The online market for unapproved injectable peptides is booming, and the FDA is struggling to keep up, as Forbes contributor Sally Pipes reports. Sellers pitch the vials as shortcuts to weight loss, muscle growth and faster recovery.
Regulators have started to push back. In August, the FDA sent warning letters to online marketers of unapproved peptides, including retatrutide, an experimental weight-loss drug still in clinical trials.
The bigger problem is the supply chain, much of which runs through overseas manufacturers. An import analysis by the Partnership for Safe Medicines found at least eight retatrutide shipments from Chinese manufacturers entered the U.S. supply chain in Q1 2026, some containing several kilograms. Bulk imports of an experimental drug by third-party suppliers, the group warns, raise significant patient-safety concerns.
The money is moving fast, too. Blockchain analytics firm Chainalysis estimated $32 million in crypto transactions with gray-market peptide vendors in Q1 2026, up 159% from the previous quarter. Meanwhile, TRM Labs reportedly identified at least 50 peptide sellers among more than 200 businesses it tracked for selling fentanyl precursors. Some have been indicted in the U.S.
Smugglers are getting creative. Customs officers in Cincinnati reportedly disrupted roughly 400 smuggling attempts carrying nearly 6,000 individual peptide orders hidden in packages labeled as ordinary goods.
Related on the SLP
Even official import safeguards have holes. In the case of China-based Harbin Jixianglong Biotech, a listed manufacturer obtained semaglutide ingredients from an unlisted facility, relabeled them and shipped them to the U.S. The FDA removed the company from its list in February.
Pipes, a scholar and think tank CEO who writes on health care, urges closer coordination between the FDA and U.S. Customs and Border Protection, more scrutiny of suppliers that misrepresent where ingredients come from, and tougher enforcement against companies that knowingly evade import restrictions. “The FDA has begun targeting illicit peptide sellers,” she writes. “Now it needs to address the supply chains that keep them in business.”
